Simcere Pharmaceutical Group (Simcere) is a holding company. The Company principally engaged in the research, development, manufacture and distribution of pharmaceutical and vaccine products in the People's Republic of China. Company markets and sells its products directly or indirectly to approximately 1,405 pharmaceutical distributors who in turn sell these products to other distributors, hospitals and retail pharmacies throughout China. As of March 31, 2013, the Company also had over 11 product candidates in various stages of development, including treatments for cancer and cardiovascular diseases. In December 2013, Simcere completed the merger contemplated by the previously announced Agreement and Plan of Merger among the Company, Simcere Holding Limited (Parent) and Simcere Acquisition Limited (Merger Sub), and as a result of the merger, the Company became a wholly owned subsidiary of Parent.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Pharmaceuticals - NEC
- Sub-Industry: N/A
- Symbol: NYSE:SCR
- CUSIP: N/A
- Web: www.simcere.com
- 50 Day Moving Avg: $8.00
- 200 Day Moving Avg: $8.00
- Trailing P/E Ratio: N/A
- P/E Growth: 0
- Net Margins: 0.62%
- Return on Equity: 1.60%
- Return on Assets: 0.33%
Frequently Asked Questions for Simcere Pharmaceutical Group (NYSE:SCR)
What is Simcere Pharmaceutical Group's stock symbol?
Simcere Pharmaceutical Group trades on the New York Stock Exchange (NYSE) under the ticker symbol "SCR."
Who are some of Simcere Pharmaceutical Group's key competitors?
Some companies that are related to Simcere Pharmaceutical Group include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis AG (NVS), Merck & Co. (MRK), Sanofi (SNY), Novo Nordisk A/S (NVO), GlaxoSmithKline PLC (GSK), Bristol-Myers Squibb Company (BMY), Eli Lilly and Company (LLY), Abbott Laboratories (ABT), AstraZeneca plc (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY) and Valeant Pharmaceuticals International (VRX).
How do I buy Simcere Pharmaceutical Group stock?
MarketBeat Community Rating for Simcere Pharmaceutical Group (NYSE SCR)MarketBeat's community ratings are surveys of what our community members think about Simcere Pharmaceutical Group and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Shares of Simcere Pharmaceutical Group can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
Consensus Ratings for Simcere Pharmaceutical Group (NYSE:SCR) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Simcere Pharmaceutical Group (NYSE:SCR)
(Data available from 7/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|9/28/2015||Royal Bank Of Canada||Reiterated Rating||Sector Perform||€34.00||N/A|
Earnings History for Simcere Pharmaceutical Group (NYSE:SCR)Earnings History by Quarter for Simcere Pharmaceutical Group (NYSE SCR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/14/2013||Q3||$0.06||$0.51||$78.50 million||$68.80 million||View||Listen|
|8/13/2013||Q2 2013||$0.12||$0.03||$91.58 million||$78.70 million||View||Listen|
|5/9/2013||Q1 2013||$0.08||$0.09||$85.10 million||View||Listen|
|3/7/2013||Q4 2012||($0.06)||$88.06 million||$86.70 million||View||Listen|
|11/15/2012||Q312||$0.07||$0.07||$85.72 million||$83.80 million||View||N/A|
Earnings Estimates for Simcere Pharmaceutical Group (NYSE:SCR)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Simcere Pharmaceutical Group (NYSE:SCR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Simcere Pharmaceutical Group (NYSE:SCR)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Simcere Pharmaceutical Group (NYSE:SCR)
Latest Headlines for Simcere Pharmaceutical Group (NYSE:SCR)
No headlines for this company have been tracked by MarketBeat.com
Simcere Pharmaceutical Group (SCR) Chart for Monday, July, 24, 2017